Experience of nevirapine use in a London cohort of HIV‐infected pregnant women

1 King's College Hospital, 2 St Thomas' Hospital, 3 St George's Hospital and 4 St Mary's Hospital, London, UK Objective  To describe the experience of four London HIV centres prescribing nevirapine (NVP) to HIV‐1 infected pregnant women with respect to immunological and virological response, tolerability and pregnancy outcome.Methods  We identified all HIV‐1‐infected women who received NVP as part of a triple antiretroviral regimen during pregnancy between January 1997 and September 1999. Laboratory results, clinical events, side‐effects and pregnancy outcome were abstracted using a standardized proforma from the medical records.Results  Forty‐six women were identified, 85% of whom were black African. At initiation of NVP, the median age was 29 years and the median baseline CD4 cell count and viral load were 242 cells/μL and 4.15 log10 copies/mL, respectively. Thirty‐two out of 36 women who had a plasma sample obtained at, or just prior to, delivery had an undetectable viral load (< 50 to